Argireline — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Argireline

Also known as: Acetyl Hexapeptide-8, Acetyl Hexapeptide-3, Ac-EEMQRR-NH2, AH8, ARG

Synthetic cosmeceutical hexapeptide; SNARE complex inhibitor / neuromuscular signaling inhibitor

Research chemicalLast updated: October 19, 2026Based on 29 peer-reviewed studies

What it is

Argireline is a synthetic peptide used in skincare products to reduce the appearance of facial wrinkles. It works by mildly interfering with the muscle signaling process that causes expression lines, similar in concept to botulinum toxin but much weaker and topical. Not FDA-approved as a drug; widely used as a cosmeceutical ingredient.

The scientific side

Argireline (Ac-EEMQRR-NH2) is a synthetic hexapeptide patterned from the N-terminal end of SNAP-25. Its primary mechanism involves interference with the formation and/or stability of the SNARE protein complex required for Ca2+-dependent exocytosis, thereby inhibiting neurotransmitter release at the neuromuscular junction with a potency reported as similar to botulinum neurotoxin A (BoNT-A), though with much lower efficacy than the neurotoxin (PMID 31811523 — NOTE: citing PMID 18498523). Specifically, it inhibits vesicle docking by preventing formation of the ternary SNARE complex and interfering with catecholamine release. In a 3D-bioengineered human skeletal muscle model, Argireline® Amplified peptide was shown to cause muscle relaxation in both healthy and aged tissue. In animal models, topical application for 6 weeks increased type I collagen fibers and decreased type III collagen fibers in aged mouse skin (PMID 23464592, PMID 23607739). Additional proposed activities identified in zebrafish models include moisturizing, anti-inflammatory, and antioxidant effects.

Class: Synthetic cosmeceutical hexapeptide; SNARE complex inhibitor / neuromuscular signaling inhibitor

Administration & storage

Administration
Topical cutaneous application (multiple studiese.g.PMID: 18498523PMID: 23417317PMID: 33151254)Subdermal injection in animal model — rat flap study (PMID: 42675285)Facial injection in a human case report (associated with infection; PMID: 33748252)Iontophoretic transdermal delivery — in vitro human excised skin (PMID: 28150423)PDO thread-mediated intradermal controlled release — proposed protocol (PMID: 38314369)
Storage
One study examining Argireline-containing cosmetic formulations noted that the methionine residue in the Argireline sequence is a point of oxidation, and that sample preparation strategy should minimize and monitor methionine oxidation to maintain product stability. Stability of emulsion formulations was evaluated by laboratory analyses, rheology tests, and in vitro release assays. No specific storage temperature or shelf-life conditions were stated in the reviewed abstracts.
Cautions
A case of Mycobacterium abscessus infection was reported following facial injection of argireline (acetyl hexapeptide-8) in a 45-year-old woman; erythema, nodules, and abscesses appeared at injection sites after one week. The condition was easily misdiagnosed as common bacterial infection. This represents the first reported such case and highlights infection risk with non-sterile or non-standardized injection procedures.,In a double-blind pilot study (n=19), the anti-wrinkle effect of Argireline added to a hyaluronic acid serum was not statistically significant (p>0.05 for all comparisons), indicating efficacy is not guaranteed.,In vitro cytotoxicity studies showed dose-dependent antiproliferation effects of argireline on HEK-293, IMR-32, and human primary skin fibroblast cells, with significant cytotoxicity observed at concentrations 18- to 10,000-fold higher than doxorubicin IC50 (depending on cell line). However, relevant cosmetic-use concentrations were not directly addressed.,The methionine residue in Argireline is susceptible to oxidation in cosmetic formulations; oxidized forms have been detected in commercial products, raising questions about stability and the active ingredient content of finished goods.,The majority of Ac-EEMQRR-amide applied topically remains on the skin surface or in the stratum corneum (0.54% HGP, 0.22% human), with minimal penetration to epidermis (0.01%) and no detectable dermis penetration in in vitro studies — this limits assumptions about depth of biological activity.,Sterile technique is essential for any injection-related procedures; the above Mycobacterium abscessus case underscores the risk of non-standardized cosmetic injection procedures.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification